Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease
Improved treatment outcomes were generally observed in patients with biologic intolerance compared to failure, especially in UC, where outcomes were similar to biologic naïve patients. Future clinical trials should meticulously differentiate prior biologic failure vs intolerance to mitigate potential bias.
Authors
- Emily C L Wong (ORCID: https://orcid.org/0000-0001-9472-201X)
- Hasan Hamam (ORCID: https://orcid.org/0009-0000-6999-3125)
- Walter Reinisch (ORCID: https://orcid.org/0000-0002-2088-091X)
- John K. Marshall (ORCID: https://orcid.org/0000-0002-0523-9032)
- Parambir S. Dulai (ORCID: https://orcid.org/0000-0002-9514-2321)
- Vipul Jairath (ORCID: https://orcid.org/0000-0002-1092-0033)
- Neeraj Narula (ORCID: https://orcid.org/0000-0002-1536-8436)
- Sunil Samnani (ORCID: https://orcid.org/0000-0003-4741-3542)
Institutions
- Northwestern University (US)
- Western University (CA)
- Institut de Recherche en Santé Digestive (FR)
- Medical University of Vienna (AT)
- McMaster University (CA)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1093/ecco-jcc/jjae151
- Citations
- 7
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.85